Literature DB >> 182141

The biochemistry of fatty liver and kidney syndrome. Biotin-mediated restoration of hepatic gluconeogenesis in vitro and its relationship to pyruvate carboxylase activity.

D W Bannister.   

Abstract

Liver slices from chicks affected by the fatty liver and kidney syndrome display an extremely low extent of hepatic gluconeogenesis which is associated with decreased activities of certain rate-limiting gluconeogenic enzymes. Pyruvate carboxylase activity is particularly severely affected, being less than 4% of control values. Incubation of affected slices in a biotin-containing nutrient medium restores both gluconeogenesis and pyruvate carboxylase actiivity (the latter to approx. 35% of the control valve). Activities of the other enzymes studied were not greatly affected by this treatment. Restoration of gluconeogenesis did not occur if biotin was excluded from the nutrient medium, nor was it prevented by protein-synthesis inhibitors. It is concluded that the syndrome involves the lack of available biotin in the liver rather than suppression of apocarboxylase synthesis.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 182141      PMCID: PMC1163728          DOI: 10.1042/bj1560167

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  20 in total

1.  The histopathology of fatty liver and kidney syndrome in chicks.

Authors:  P A Wight; W G Siller
Journal:  Res Vet Sci       Date:  1975-09       Impact factor: 2.534

2.  The involvement of dietary fat and vitamins, stress, litter and starvation on the incidence of the fatty liver and kidney syndrome in chicks.

Authors:  C C Whitehead; R Blair; D W Bannister; A J Evans
Journal:  Res Vet Sci       Date:  1975-01       Impact factor: 2.534

3.  The effect of dietary fat and protein levels, form and cereal type on fatty liver and kidney syndrome in chicks.

Authors:  R Blair; C C Whitehead; P W Teague
Journal:  Res Vet Sci       Date:  1975-01       Impact factor: 2.534

4.  Evidence for a lesion in carbohydrate metabolism in fatty liver and kidney syndrome in chicks.

Authors:  D W Bannister; A J Evans; C C Whitehead
Journal:  Res Vet Sci       Date:  1975-03       Impact factor: 2.534

5.  Some aspects of lipid metabolism in fatty liver and kidney syndrome in chicks.

Authors:  A J Evans; D W Bannister; C C Whitehead
Journal:  Res Vet Sci       Date:  1975-01       Impact factor: 2.534

6.  Hepatic gluconeogenesis in chicks: effect of biotin on gluconeogenesis in biotin-deficiency and fatty liver and kidney syndrome.

Authors:  D W Bannister
Journal:  Comp Biochem Physiol B       Date:  1976

7.  Histopathology of the adrenal glands in the fatty liver and kidney syndrome of chickens.

Authors:  P A Wight
Journal:  J Comp Pathol       Date:  1975-10       Impact factor: 1.311

8.  Fatty liver and kidney syndrome in chicks. Effects on liver and kidney of diets causing the syndrome.

Authors:  C C Whitehead; D W Bannister; R Blair; A J Evans
Journal:  Res Vet Sci       Date:  1974-09       Impact factor: 2.534

9.  Carbohydrate absorption by chicks affected with the fatty liver and kidney syndrome.

Authors:  D W Bannister; A J Evans; C C Whitehead
Journal:  Res Vet Sci       Date:  1975-07       Impact factor: 2.534

10.  Biotin deficiency and fatty liver and kidney syndrome in chicks given purified diets containing different fat and protein levels.

Authors:  C C Whitehead; D W Bannister; A J Evans; W G Siller; P A Wight
Journal:  Br J Nutr       Date:  1976-01       Impact factor: 3.718

View more
  2 in total

1.  Based on network pharmacology method to discovered the targets and therapeutic mechanism of Paederia scandens against nonalcoholic fatty liver disease in chicken.

Authors:  Qiang Wu; Fan Yang; Huaqiao Tang
Journal:  Poult Sci       Date:  2020-10-20       Impact factor: 3.352

2.  The Anti-Oxidation and Mechanism of Essential Oil of Paederia scandens in the NAFLD Model of Chicken.

Authors:  Qiang Wu; Huaqiao Tang; Hongbin Wang
Journal:  Animals (Basel)       Date:  2019-10-22       Impact factor: 2.752

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.